Immunotherapy has significantly transformed the therapeutic landscape in modern oncology, with immune checkpoint inhibitors (ICIs) such as anti-PD-1, anti-PD-L1, and anti-CTLA4 emerging as established standards of care for various tumor types, particularly at advanced stages. Here, CD274 is linked to neoplasm.